Malignant pheochromocytoma

Frontiers of Hormone Research

Volumn 31, Issue , 2004, Pages 155-162

  Lehnert, Hendrik ^a   Mundschenk, Jochen ^a   Hahn, Klaus ^b  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33845490747     PISSN: 03013073     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (38)

1. Kopf D, Goretzki P, Lehnert H: Clinical management of malignant adrenal tumors. Cancer Res Clin Oncol 2001;127:143-155.
2. Mundschenk J, Lehnert H: Malignant pheochromocytoma. Exp Clin Endocrinol Diabetes 1998;106:373-376.
3. Proye C, Vix M, Jansson S, Tisell LE, Dralle H, Hiller W: The phaeochromocytoma - A benign, intraadrenal, hypertensive, sporadic unilateral tumor. Does it exist? World J Surg 1994;18:467-472.
4. Mornex R, Badet C, Peyrin L: Malignant pheochromocytoma: A series of 14 cases observed between 1966 and 1990. J Endocrinol Invest 1992;15:643-649.
5. Proye C, Vix M, Goropoulos A, Kerlo P, Lecomte-Houcke M: High incidence of malignant pheochromocytoma in a surgical unit: 26 cases out of 100 patients operated from 1971 to 1991. J Endocrinol Invest 1992;15:651-663.
6. Clarke MR, Weyant RJ, Watson CG, Carty SE: Prognostic markers in pheochromocytoma. Hum Pathol 1998;28:522-526.
7. Brown HM, Komorowski RA, Wilson SD, Demeure MJ, Zhu Y: Predicting metastasis of pheochromocytomas using DNA flow cytometry and immunohistochemical markers of cell proliferation. Cancer 1999;86:1583-1589.
8. Khorram-Manesh A, Ahlman H, Jansson S, Nilsson O: N-cadherin expression in adrenal tumors: Upregulation in malignant pheochromocytoma and downregulation in adrenocortical carcinoma. Endocr Pathol 2002;13:99-110.
9. Salmenkivi K, Haglund C, Ristimati A, Arola J, Heikkila P: Increased expression of cyclooxygenase-2 in malignant pheochromocytomas. J Clin Endocrinol Metab 2001;86:5615-5619.
10. Boltze C, Mundschenk J, Linger N, Schneider-Stock R, Mawrin C, Hoang-Vu C, Roessner A, Lehnert H: Expression profile of the telomeric complex discriminates between benign and malignant pheochromocytoma. J Clin Endocrinol Metab, in press.
11. Thompson LD: Pheochromocytoma of the adrenal gland scaled score (PASS) to separate benign from malignant neoplasms: A clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol 2002;26:551-566.
12. Jacob T, Lescout JM, Bussy E: Malignant diaphragmatic pheochromocytoma. Clin Nucl Med 2002;27:807-809.
13. Kaltsas GA, Papadogias D, Grossman AB: The clinical presentation (symptoms and signs) of sporadic and familial chromaffin cell tumours (phaeochromocytomas and paragangliomas); in Lehnert H (ed): Pheochromocytoma. Pathophysiology and Clinical Management. Front Horm Res. Basel, Karger, 2004, vol 31, pp 61-75.
14. Liel Y, Zucker G, Lantsberg S, Argov S, Zirkin HJ: Malignant pheochromocytoma simulating meningioma: Coexistence of recurrent meningioma and metastatic pheochromocytoma in the base of the skull. Isr Med Assoc J 2002;4:829-831.
15. Srinivasan R, Kini U, Babu MK, Jayaseelan E, Pradeep R: Malignant pheochromocytoma with cutaneous metastases presenting with hemolytic anemia and pyrexia of unknown origin. J Assoc Physicians India 2002;50:731-733.
16. Yanagi Y, Asaumi J, Hisatomi M, Konouchi H, Wakasa T, Kishi K: Mandibular metastasis presenting as the initial manifestation of malignant pheochromocytoma. Eur J Radiol 2002;44:5-9.
17. Turner N, Brown JW, Carballeira A, Fishman LM: Tyrosine hydroxylase gene expression in varying forms of human pheochromocytoma. Life Sci 1996;19:1659-1665.
18. Oishi S, Sato T: Elevated serum neuron-specific enolase in patients with malignant pheochromocytoma. Cancer 1988;61:1167-1170.
19. Epelbaum J, Bertherat J, Prevost G, Kordon C, Meyerhof W, Wulfsen I, Richter D, Plouin PF: Molecular and pharmacological characterization of somatostatin receptor subtypes in adrenal, extraadrenal and malignant pheochromocytomas. J Clin Endocrinol Metab 1995;80:1837-1844.
20. Mundschenk J, Linger N, Schulz S, Höllt V, Schulz S, Steinke R, Lehnert H: Somatostatin receptor subtyping in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy. J Clin Endocrinol Metab, in press.
21. Reubi JC, Waser B, Liu Q, Laissne JA, Schonbrunn A: Subcellular distribution of somatostatin sst2A receptors in human tumors of the nervous and neuroendocrine systems: Membranous versus intracellular location. J Clin Endocrinol Metab 2000;85:3882-3891.
22. Kaltsas G, Korbonits M, Heintz E, et al: Comparison of somatostatin analog and metaiodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab 2001;86:895-902.
23. Kopf D, Bockisch A, Steinert H, Hahn K, Beyer J, Neumann HP, Hensen J, Lehnert H: Octreotide scintigraphy and catecholamine response to an octreotide challenge in malignant pheochromocytoma. Clin Endocrinol 1997;46:39-44.
24. Tennebaum F, Lumbroso J, Schlumberger M, Mure A, Plouin PF, Caillou B, Parmentier C: Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma. J Nucl Med 1995;36:1-6.
25. 111In] octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab 2001;86:685-693.
26. Pacak K, Linehan WM, Eisenhofer G, Walther MM, Goldstein DS: Recent advances in genetics, diagnosis, localization and treatment of pheochromocytoma. Ann Intern Med 2001;134:315-329.
27. Shulkin BL, Thompson NW, Shapiro B, Francis IR, Sisson JC: Pheochromocytoma imaging with 2-deoxy-D-glucose PET. Radiology 1999;212:35-41.
28. Yamamoto A, Zhuang H, Alavi A: Detection of cranial metastases by F-18 FDG positron emission tomography. Clin Nucl Med 2001;26:402-404.
29. Pacak K, Eisenhofer G, Carrasguillo JA, Chen CC, Li ST, Goldstein DS: 6-[18F] fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension 2001;38:6-8.
30. Hwang JJ, Uchio EM, Patel SV, Linehan WM, Walther MM, Pacak K: Diagnostic localization of malignant bladder pheochromocytoma using 6-18F fluorodopamine positron emission tomography. J Urol 2003;169:274-275.
31. Pacak K, Eisenhofer G, Ilias I: Diagnostic imaging of pheochromocytoma; in Lehnert H (ed): Pheochromocytoma. Pathophysiology and Clinical Management. Front Horm Res. Basel, Karger, 2004, vol 31, pp 107-120.
32. Hoefnagel CA: Metaiodobenzylguanidine and somatostatin in oncology: Role in the management of neural crest tumors. Eur J Nucl Med 1994;21:561-581.
33. Loh KC, Fitzgerald PA, Matthay KK, Yeo PB, Price DC: The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine. A comprehensive review of 116 patients. J Endocrinol Invest 1997;20:648-658.
34. Mukherjee J, Kaltgas G, Islam N, et al: Treatment of metastatic carcinoid tumors, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)1-metaiodobenzylguanidine. Clin Endocrinol 2001;55:47-60.
35. 111In-DTPA-octreotide. Eur J Nucl Med 2001;28:1743-1750.
36. Averbuch SD, Steakley CS, Young RC, Gelman EP, Goldstein DS, Stull R, Keiser HR: Malignant pheochromocytoma: Effective treatment with a combination of cyclophosphamide, vincristine and dacarbazine. Ann Intern Med 1988;109:267-273.
37. 125I-metaiodobenzylguanidine uptake in human neuroblastoma cell lines. Eur J Cancer 1999;35:1227-1234.
38. 131I-metaiodobenzylguanidine and chemotherapy. Am J Clin Oncol 1999;22:364-370.